FDA Approves Merck’s Dificid for Pediatric PatientsApprovals, Clostridium Difficile-Associated Diarrhea, FDA, FDA/Regulatory, New Formulations, New Indications, PediatricThe U.S. Food and Drug Administration approved Merck’s Dificid (fidaxomicin) for a new oral suspension as well as for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in children ages 6 months and older. Read more January 27, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Merck-Diffcid-Approval-BioSpace-1-27-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-01-27 12:20:392020-01-28 10:56:52FDA Approves Merck’s Dificid for Pediatric Patients